Recruiting nowPhase 2Ages 18 Years and up
Phase II Trial of Lung Chemoemobolization
Sponsor: City of Hope Medical Center · NCT05672108 on ClinicalTrials.gov ↗
Conditions studied
Lung Non-Small Cell CarcinomaMediastinal NeoplasmPleural NeoplasmLung Metastases From Any PrimaryEndobronchial MetastasesColon CancerSarcoma
What it tests
- Computed Tomographyprocedure
- Ethiodized Oildrug
- Mitomycindrug
- Transarterial Chemoembolizationprocedure
- Tris-acryl Gelatin Microspheresdevice
Where it's running2 sites
- Recruiting now
City of Hope Medical Center
Duarte, California 91010
- Franz E. Boas(contact)626-218-8708[email protected]
- Franz E. Boas(principal investigator)
- Recruiting now
Memorial Sloan Kettering Cancer Center
New York, New York 10065
- Stephen B. Solomon, MD(contact)212-639-5012[email protected]
- Stephen B. Solomon, MD(principal investigator)
See the official eligibility language
Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.
Inclusion Criteria: * Lung cancer or lung metastases, with lung, endobronchial, pleural, or mediastinal tumors that are progressing on systemic therapy (or the patient cannot tolerate systemic therapy), and that are not amenable to resection, thermal ablation, or ablative radiation therapy * Lung-dominant disease (majority of active tumor volume is in the chest) * At least 18 years old Exclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status \> 2 * Oxygen saturation \< 92% on room air * Forced expiratory volume in 1 second (FEV1) \< 60% * No measurable treatable disease, per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (for example, unable to measure tumor size on CT, or lung nodules are all \< 1 cm) * Life expectancy \< 6 months * Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, magnetic resonance imaging \[MRI\], or direct pressure measurement) * Recent pulmonary embolism (within 3 months) * Pulmonary arteriovenous malformation * Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month) * Symptomatic heart failure (American College of Cardiology \[ACC\]/American Heart Association \[AHA\] stage C or D) * Left bundle branch block (contraindication to pulmonary angiography) * Renal failure (estimated glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73 m\^2) * Pregnancy or intent to become pregnant * Breast feeding * Altered mental status that would interfere with consent or follow-up * Platelets \< 50,000 (after transfusion, if needed) * International normalized ratio (INR) \> 2 (after transfusion, if needed) * Hemoglobin \< 7 (after transfusion, if needed) * Hyperthyroidism or history of hyperthyroidism, including subclinical hyperthyroidism (contraindication to lipiodol) * Planned radioactive iodine imaging or therapy (contraindication to lipiodol) * Allergy to lipiodol or mitomycin * Allergy to iodinated contrast that cannot be treated with steroid / diphenhydramine premedication * Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, or that would affect subject safety
Updated 2026-03-05 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.